AXLA

Noble Financial analyst Robert LeBoyer maintained a Buy rating on Axcella Health (AXLA – Research Report) today and set a price target of $9.00. The company's shares closed last Friday at $1.96, close to its 52-week low of $1.35. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 9.4% and a 32.5% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Ayala Pharmaceuticals, and Onconova Therapeutics. Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $9.20, a 374.2% upside from current levels.
https://www.tipranks.com/news/blurbs/axcella-health-axla-receives-a-buy-from-noble-financial?utm_source=advfn.com&utm_medium=referral